Health Care & Life Sciences » Biotechnology | Helix BioPharma Corp.

Helix BioPharma Corp.

Helix BioPharma Corp.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
103.49 M
Public Float
-
Helix BioPharma Corp.
Stock Exchange Toronto Stock Exchange Prices
EPS
CAD0.07
Market Cap
CAD27.81 M
Shares Outstanding
111.23 M
Public Float
95.67 M

Profile

Address
9120 Leslie Street
Richmond Hill Ontario L4B 3J9
Canada
Employees -
Website http://www.helixbiopharma.com
Updated 07/08/2019
Helix BioPharma Corp. is a clinical stage biopharmaceutical company, which develops products for the treatment and prevention of cancer. It focuses on the development and commercialization of innovative medicines in the areas of cancer prevention and treatment. Its product portfolio includes Topical Interferon Alpha-2b DOS47, Orthovisc, Monovisc, Normacol, Car-T, Imunovir and Klean-Prep.

Financials

View All

Slawomir Majewski
Chairman
Heman Chao
Director, Chief Executive & Scientific Officer